FindTrial
Sign In

NTX-301

DRUG2 trials

Sponsors

University of Alabama at Birmingham, Xennials Therapeutics Australia Pty Ltd

Conditions

Acute Myeloid LeukemiaAdvanced Solid TumorChronic Myelomonocytic LeukemiaHigh-grade GliomaMyelodysplastic SyndromesPlatinum-Resistant Ovarian CancerPlatinum-Resistant Urothelial Carcinoma

Phase 1

NTX-301 in MDS/AML
Active, not recruitingNCT04167917
University of Alabama at BirminghamAcute Myeloid Leukemia, Chronic Myelomonocytic Leukemia, Myelodysplastic Syndromes
Start: 2021-01-06End: 2026-03-31Updated: 2025-09-24
NTX-301 Monotherapy in Advanced Solid Tumours and in Combination With Platinum-based Chemotherapy in Advanced Ovarian & Bladder Cancer and in Combination With Temozolomide in High-grade Glioma
TerminatedNCT04851834
Xennials Therapeutics Australia Pty LtdAdvanced Solid Tumor, High-grade Glioma, Platinum-Resistant Ovarian Cancer +1
Start: 2021-08-25End: 2022-11-08Updated: 2022-12-20

Related Papers

A phase 1 study of NTX-301, an oral DNMT1 inhibitor, in patients with MDS and AML (trial in progress).
Journal of Clinical Oncology2022-06-014 citations